Liver hemangioma and vascular liver diseases in patients with systemic lupus erythematosus

Table 2 Clinical and laboratory characteristics of systemic lupus erythematosus patients according to the presence and number of hepatic hemangioma

	Patients with HH(n = 19)	SingleHH(n = 12)	Multiple HH(n = 7)	Patients without HH (n = 16)
Age (yr)	51 ± 16	52 ± 17	52 ± 17	49 ± 18
Gender (M/F)	2/17	2/10	0/7	0/16
SLE duration (yr)	7.1 ± 6.4	5.5 ± 6.4	9.9 ± 6.5a	6.8 ± 6.1
Clinical flares (n)	3.5 ± 1.8	2.9 ± 1.4	4.2 ± 2.1	2.7 ± 1.4
SLEDAI1	8.3 ± 4.3	8.9 ± 5.1	7.4 ± 2.6	10.0 ± 4.3
ACR/SLICC1	2.3 ± 1.9	2.0 ± 1.7	3.0 ± 2.0	1.9 ± 1.4
Acrocyanosis1 (%)	94.4	100.0	85.7	43.8b
Steroid treatment (%)1	75.0	60.0	100.0	87.5
Yr of steroid Rx (yr)1	6.8 ± 6.2	8.2 ± 7.1	5.5 ± 5.6	6.6 ± 6.1
LAC positivity (%)	22.2	18.2	28.6	25.0
AST (U/L)	23 ± 11	25 ± 14	21 ± 4	21 ± 7
ALT (U/L)	18 ± 6	17 ± 6	20 ± 8	19 ± 11
Bilirubin (mg/dL)	0.7 ± 0.5	0.7 ± 0.7	0.7 ± 0.3	0.5 ± 0.2
GGT (U/L)	36 ± 54	42 ± 65	23 ± 9	29 ± 28
ALP (U/L)	213 ± 133	243 ± 134	169 ± 138	168 ± 65

¹Data available in n = 33.

^aP < 0.05 vs patients with single hepatic hemangioma and

^bP = 0.02 vs patients with hepatic hemangioma. M: Male; F: Female; SLE: Systemic lupus erythematosus; SLEDAI: Systemic lupus erythematosus disease activity index; SLICC: Systemic lupus international collaborating clinics; ACR: American college of rheumatology damage index for systemic lupus erythematosus; LAC: Lupus anticoagulant; AST: Aspartate transaminase; ALT: Alanine transaminase; GGT: Gamma-glutamyl transpeptidase; ALP: Alkaline phosphatase; HH: Hepatic hemangioma.